WO2005113495A1 - Verfahren zur herstellung von diphenyl-azetidinon-derivaten - Google Patents
Verfahren zur herstellung von diphenyl-azetidinon-derivaten Download PDFInfo
- Publication number
- WO2005113495A1 WO2005113495A1 PCT/EP2005/005497 EP2005005497W WO2005113495A1 WO 2005113495 A1 WO2005113495 A1 WO 2005113495A1 EP 2005005497 W EP2005005497 W EP 2005005497W WO 2005113495 A1 WO2005113495 A1 WO 2005113495A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aryl
- alkyl
- och
- general formula
- mmol
- Prior art date
Links
- VDOXIAUNJCHYRC-UHFFFAOYSA-N 1,3-diphenylazetidin-2-one Chemical class O=C1C(C=2C=CC=CC=2)CN1C1=CC=CC=C1 VDOXIAUNJCHYRC-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 27
- 150000002466 imines Chemical class 0.000 claims abstract description 18
- 125000006239 protecting group Chemical group 0.000 claims abstract description 18
- 125000001424 substituent group Chemical group 0.000 claims abstract description 10
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 60
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 229960003908 pseudoephedrine Drugs 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 150000002148 esters Chemical class 0.000 claims description 14
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 13
- 238000006459 hydrosilylation reaction Methods 0.000 claims description 13
- 150000004702 methyl esters Chemical class 0.000 claims description 13
- 238000010511 deprotection reaction Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000000468 ketone group Chemical group 0.000 claims description 6
- 229930194542 Keto Natural products 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 150000008064 anhydrides Chemical class 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 claims description 3
- 239000000543 intermediate Substances 0.000 claims description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 2
- 150000003951 lactams Chemical class 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- NUYDHIAZJRTXQB-UHFFFAOYSA-N 5-hydroxy-5-phenylpentanoic acid Chemical compound OC(=O)CCCC(O)C1=CC=CC=C1 NUYDHIAZJRTXQB-UHFFFAOYSA-N 0.000 claims 1
- SHKWSBAVRQZYLE-UHFFFAOYSA-N 5-oxo-5-phenylpentanoic acid Chemical compound OC(=O)CCCC(=O)C1=CC=CC=C1 SHKWSBAVRQZYLE-UHFFFAOYSA-N 0.000 claims 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 135
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 111
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
- 239000000047 product Substances 0.000 description 103
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 102
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 75
- 238000004128 high performance liquid chromatography Methods 0.000 description 70
- 239000000203 mixture Substances 0.000 description 62
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 61
- -1 substituted-amino Chemical group 0.000 description 58
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 57
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 46
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 44
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 42
- 150000001408 amides Chemical class 0.000 description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 38
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- 239000011541 reaction mixture Substances 0.000 description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- 239000012071 phase Substances 0.000 description 35
- 238000003756 stirring Methods 0.000 description 35
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 34
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 26
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 25
- 239000007858 starting material Substances 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000012043 crude product Substances 0.000 description 24
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 23
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 23
- 239000002904 solvent Substances 0.000 description 23
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 22
- 239000003921 oil Substances 0.000 description 22
- 239000007787 solid Substances 0.000 description 22
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 21
- 229960000583 acetic acid Drugs 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- 239000002585 base Substances 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 17
- 239000008346 aqueous phase Substances 0.000 description 17
- 229910052786 argon Inorganic materials 0.000 description 17
- 229910052744 lithium Inorganic materials 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- 239000003480 eluent Substances 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 12
- 239000008259 solid foam Substances 0.000 description 12
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 229920001843 polymethylhydrosiloxane Polymers 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000011521 glass Substances 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 10
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 9
- 101150065749 Churc1 gene Proteins 0.000 description 9
- 102100038239 Protein Churchill Human genes 0.000 description 9
- 229910052796 boron Inorganic materials 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 238000006345 epimerization reaction Methods 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000003109 Karl Fischer titration Methods 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000006470 amide elimination reaction Methods 0.000 description 8
- 229940043279 diisopropylamine Drugs 0.000 description 8
- 239000012362 glacial acetic acid Substances 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 7
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 7
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 7
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 229910003002 lithium salt Inorganic materials 0.000 description 7
- 159000000002 lithium salts Chemical class 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 229910000077 silane Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 6
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 6
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 6
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 6
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 239000005749 Copper compound Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 235000011089 carbon dioxide Nutrition 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 150000001880 copper compounds Chemical class 0.000 description 5
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 5
- 229910000071 diazene Inorganic materials 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- UNLBEUJPMNQIRT-NSHDSACASA-N methyl (5s)-5-(4-fluorophenyl)-5-hydroxypentanoate Chemical compound COC(=O)CCC[C@H](O)C1=CC=C(F)C=C1 UNLBEUJPMNQIRT-NSHDSACASA-N 0.000 description 5
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical group C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 150000003952 β-lactams Chemical class 0.000 description 5
- ICVAKZDQBUXFBI-DSNGMDLFSA-N (2r,5s)-2-[(s)-[4-(aminomethyl)anilino]-(4-methoxyphenyl)methyl]-5-(4-fluorophenyl)-5-hydroxypentanoic acid Chemical compound C1=CC(OC)=CC=C1[C@H]([C@@H](CC[C@H](O)C=1C=CC(F)=CC=1)C(O)=O)NC1=CC=C(CN)C=C1 ICVAKZDQBUXFBI-DSNGMDLFSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 4
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 230000005587 bubbling Effects 0.000 description 4
- KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 description 4
- TVNYNMWSTIOQCP-UHFFFAOYSA-N methyl 5-(4-fluorophenyl)-5-oxopentanoate Chemical compound COC(=O)CCCC(=O)C1=CC=C(F)C=C1 TVNYNMWSTIOQCP-UHFFFAOYSA-N 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 238000006277 sulfonation reaction Methods 0.000 description 4
- 0 **(C=CC1)C=C[C@]1N=CC1=C*C=CC=C1 Chemical compound **(C=CC1)C=C[C@]1N=CC1=C*C=CC=C1 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000006519 CCH3 Chemical group 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000006683 Mannich reaction Methods 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical group O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 3
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 3
- 239000012482 calibration solution Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000005595 deprotonation Effects 0.000 description 3
- 238000010537 deprotonation reaction Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 239000012041 precatalyst Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 150000004760 silicates Chemical class 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- UHUUYVZLXJHWDV-UHFFFAOYSA-N trimethyl(methylsilyloxy)silane Chemical compound C[SiH2]O[Si](C)(C)C UHUUYVZLXJHWDV-UHFFFAOYSA-N 0.000 description 3
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- GCBWDZYSLVSRRI-UHFFFAOYSA-N 3-aminoazetidin-2-one Chemical compound NC1CNC1=O GCBWDZYSLVSRRI-UHFFFAOYSA-N 0.000 description 2
- BFWYZZPDZZGSLJ-UHFFFAOYSA-N 4-(aminomethyl)aniline Chemical compound NCC1=CC=C(N)C=C1 BFWYZZPDZZGSLJ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- ZNORAFJUESSLTM-UHFFFAOYSA-N [4-[5-bis(3,5-ditert-butyl-4-methoxyphenyl)phosphanyl-1,3-benzodioxol-4-yl]-1,3-benzodioxol-5-yl]-bis(3,5-ditert-butyl-4-methoxyphenyl)phosphane Chemical compound C1=C(C(C)(C)C)C(OC)=C(C(C)(C)C)C=C1P(C=1C(=C2OCOC2=CC=1)C=1C(=CC=C2OCOC2=1)P(C=1C=C(C(OC)=C(C=1)C(C)(C)C)C(C)(C)C)C=1C=C(C(OC)=C(C=1)C(C)(C)C)C(C)(C)C)C1=CC(C(C)(C)C)=C(OC)C(C(C)(C)C)=C1 ZNORAFJUESSLTM-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- JJFLDSOAQUJVBF-UHFFFAOYSA-N copper monohydride Chemical compound [CuH] JJFLDSOAQUJVBF-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960000815 ezetimibe Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000006263 metalation reaction Methods 0.000 description 2
- JVLYVPVOHKFOOG-AWEZNQCLSA-N methyl (2S)-2-(ethoxymethoxy)-5-(4-fluorophenyl)pentanoate Chemical compound COC([C@H](CCCC1=CC=C(C=C1)F)OCOCC)=O JVLYVPVOHKFOOG-AWEZNQCLSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- BDOLXPFAFMNDOK-UHFFFAOYSA-N oxazaborolidine Chemical compound B1CCON1 BDOLXPFAFMNDOK-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- HUPQYPMULVBQDL-UHFFFAOYSA-N pentanoic acid Chemical compound CCCCC(O)=O.CCCCC(O)=O HUPQYPMULVBQDL-UHFFFAOYSA-N 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 238000011894 semi-preparative HPLC Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 241000894007 species Species 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- YFNKIDBQEZZDLK-UHFFFAOYSA-N triglyme Chemical compound COCCOCCOCCOC YFNKIDBQEZZDLK-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- FZHWTOFRSKTHQM-OZNIXHKMSA-N (2r,5s)-2-[(s)-[4-(aminomethyl)anilino]-(4-methoxyphenyl)methyl]-5-(ethoxymethoxy)-5-(4-fluorophenyl)pentanoic acid Chemical compound N([C@@H]([C@@H](CC[C@H](OCOCC)C=1C=CC(F)=CC=1)C(O)=O)C=1C=CC(OC)=CC=1)C1=CC=C(CN)C=C1 FZHWTOFRSKTHQM-OZNIXHKMSA-N 0.000 description 1
- ZIFWYCYPTCFKCS-DSNGMDLFSA-N (3r,4s)-1-[4-(aminomethyl)phenyl]-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-methoxyphenyl)azetidin-2-one Chemical compound C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(CN)=CC=2)C(=O)[C@@H]1CC[C@H](O)C1=CC=C(F)C=C1 ZIFWYCYPTCFKCS-DSNGMDLFSA-N 0.000 description 1
- RUKURQIBVNJZAB-DYIKCSJPSA-N (3r,4s)-1-[4-(aminomethyl)phenyl]-3-[(3s)-3-[tert-butyl(dimethyl)silyl]oxy-3-(4-fluorophenyl)propyl]-4-(4-methoxyphenyl)azetidin-2-one Chemical compound C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(CN)=CC=2)C(=O)[C@@H]1CC[C@H](O[Si](C)(C)C(C)(C)C)C1=CC=C(F)C=C1 RUKURQIBVNJZAB-DYIKCSJPSA-N 0.000 description 1
- FSXKAGUHLIGGRG-JTQLQIEISA-N (5s)-5-(4-fluorophenyl)-5-hydroxypentanoic acid Chemical compound OC(=O)CCC[C@H](O)C1=CC=C(F)C=C1 FSXKAGUHLIGGRG-JTQLQIEISA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- VMKAFJQFKBASMU-QGZVFWFLSA-N (r)-2-methyl-cbs-oxazaborolidine Chemical compound C([C@@H]12)CCN1B(C)OC2(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-QGZVFWFLSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- HZVHFGGPXITZGN-UHFFFAOYSA-N 1,4-diphenylazetidin-2-one Chemical class O=C1CC(C=2C=CC=CC=2)N1C1=CC=CC=C1 HZVHFGGPXITZGN-UHFFFAOYSA-N 0.000 description 1
- WIJROYGHVFFKQY-UHFFFAOYSA-N 1-(4-methoxyphenyl)-n-[[4-[(4-methoxyphenyl)methylideneamino]phenyl]methyl]methanimine Chemical compound C1=CC(OC)=CC=C1C=NCC1=CC=C(N=CC=2C=CC(OC)=CC=2)C=C1 WIJROYGHVFFKQY-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- YBONBWJSFMTXLE-UHFFFAOYSA-N 2,3-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1Cl YBONBWJSFMTXLE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- ZBQROUOOMAMCQW-UHFFFAOYSA-N 5-(4-fluorophenyl)-5-oxopentanoic acid Chemical compound OC(=O)CCCC(=O)C1=CC=C(F)C=C1 ZBQROUOOMAMCQW-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- CUUYHTKJMSYYFA-HTAPYJJXSA-N C[C@@H]([C@H](c1ccccc1)O)N(C)C(CCCC1(c(cc2)ccc2F)OCCO1)=O Chemical compound C[C@@H]([C@H](c1ccccc1)O)N(C)C(CCCC1(c(cc2)ccc2F)OCCO1)=O CUUYHTKJMSYYFA-HTAPYJJXSA-N 0.000 description 1
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000005750 Corey-Bakshi-Shibata reduction reaction Methods 0.000 description 1
- 229910016509 CuF 2 Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 1
- FFKZOUIEAHOBHW-UHFFFAOYSA-N N,4-dimethyl-N-nitrosobenzenesulfonamide Chemical compound O=NN(C)S(=O)(=O)C1=CC=C(C)C=C1 FFKZOUIEAHOBHW-UHFFFAOYSA-N 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 238000006995 Noyori hydrogenation reaction Methods 0.000 description 1
- 108010038807 Oligopeptides Chemical group 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229910020175 SiOH Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- RZZDRSHFIVOQAF-UHFFFAOYSA-N [4-(5-diphenylphosphanyl-1,3-benzodioxol-4-yl)-1,3-benzodioxol-5-yl]-diphenylphosphane Chemical compound C=12OCOC2=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1C1=C2OCOC2=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RZZDRSHFIVOQAF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- JTXJZBMXQMTSQN-UHFFFAOYSA-N amino hydrogen carbonate Chemical compound NOC(O)=O JTXJZBMXQMTSQN-UHFFFAOYSA-N 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000004697 chelate complex Chemical class 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005837 enolization reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- KQIWSIMHXWXWRS-LJAQVGFWSA-N methyl (2S)-2-(4-fluorophenyl)-5-trityloxypentanoate Chemical compound COC([C@@H](CCCOC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=C(C=C1)F)=O KQIWSIMHXWXWRS-LJAQVGFWSA-N 0.000 description 1
- ZDGSBDJYFAGNOA-INIZCTEOSA-N methyl (2S)-2-[tert-butyl(dimethyl)silyl]oxy-5-(4-fluorophenyl)pentanoate Chemical compound COC([C@H](CCCC1=CC=C(C=C1)F)O[Si](C)(C)C(C)(C)C)=O ZDGSBDJYFAGNOA-INIZCTEOSA-N 0.000 description 1
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 1
- OKHRRIGNGQFVEE-UHFFFAOYSA-N methyl(diphenyl)silicon Chemical compound C=1C=CC=CC=1[Si](C)C1=CC=CC=C1 OKHRRIGNGQFVEE-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HNBDRPTVWVGKBR-UHFFFAOYSA-N n-pentanoic acid methyl ester Natural products CCCCC(=O)OC HNBDRPTVWVGKBR-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- HZUNGJHYCYQRIB-UHFFFAOYSA-N perchloric acid tetrahydrate Chemical compound O.O.O.O.O[Cl](=O)(=O)=O HZUNGJHYCYQRIB-UHFFFAOYSA-N 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- WILBTFWIBAOWLN-UHFFFAOYSA-N triethyl(triethylsilyloxy)silane Chemical compound CC[Si](CC)(CC)O[Si](CC)(CC)CC WILBTFWIBAOWLN-UHFFFAOYSA-N 0.000 description 1
- SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- a silylating agent and a fluoride ion catalyst as the cyclizing agent or a salt of the chiral compound (G + salt), in particular with bis (trimethylsilyl) acetamide and tefra-n-butylammonium fluoride.
- a disadvantage of this process is the use of large amounts of silylating agents such as N, O-bis (trimethylsilyl) acetamide, since the workup produces acetamide, which is classified as carcinogenic.
- the diastereoselectivity is rather moderate during the addition reaction stage using enolate and 1 min, which means that additional separation stages are necessary.
- R 1 OH, OCH 3
- R 2 F, CH 2 CH 3 , CH 2 NHR 4
- R 5 OH, NH-CH 2 - [CH (OH) -] m CH 2 OH
- R 8 R 2 , CH 2 N [Si (alkyl) 0 (aryl) p ] CO 2 CH 2 (C 6 H 5 ), CH 2 N [Si (alkyl) 0 (aryl) p ] CO 2 tert-butyl .
- asymmetric hydrosilylation succeeds at high concentration in the solvent toluene (see Examples 32 and 33), while the CBS reduction is usually carried out at a larger dilution and in less technically desirable solvents such as dichloromethane or THF.
- the advantage of asymmetric hydrosilylation over Noyori's asymmetric Ru (H) -catalyzed hydrogenation mainly consists in the low catalyst costs.
- the asymmetric hydrosilylation takes place over a chirally complexed CuH catalyst that is generated in situ from an inexpensive copper ( ⁇ ) salt (e.g. CuCl), the ligand and the silane, preferably PMHS, in the reaction solvent (e.g. toluene).
- the free one is , uncomplexed portion of the CuH is thermally unstable.
- this decomposition is suppressed by carrying out the in-situ production of the CuH (for example from CuCl) in the presence of one equivalent of triphenylphosphine based on CuH, or alternatively using preformed Stryker reagent as the precatalyst.
- the asymmetric hydrosilylation of the ketone can be carried out in such a way that the reaction product is either isolated directly from the free, optically active alcohol, or its silyl ether, which can then be deprotected to give the free alcohol can, or can continue to implement in the protected form.
- Use of PMHS and direct isolation of the free, optically active alcohol often gives better results and is therefore preferred.
- the use of other silanes, e.g. B. TBS-H or TES-H, followed by the isolation of the tert-butyldimethylsilyl ether or the triethylsilyl ether of the chiral alcohol but also belongs to the embodiments of the present invention.
- Silyl protective groups the trityl, the THP, the 1-ethoxyethyl and the alkoxymethyl protective groups, and the tert are particularly preferred.
- the protective groups are introduced by methods known to the person skilled in the art, such as, for. B. in "Protective Groups in Organic Synthesis” Third Edition [TW Green, PGM Wuts (Editor), John Wiley & Sons, Inc., 1999] are described.
- the imine component (DI) required for the subsequent addition is obtained from the corresponding aniline derivative and aldehyde by known methods.
- the water formed in the reaction can be removed, for example, by azeotropic distillation with toluene.
- the enolate is produced from the amide (XI) with the appropriate bases and this is added to the lnine (DI).
- General examples of this are described in J. Org. Chem. (2001, volume 66, pages 9030-9032), Organic Letters (2001, volume 3, pages 773-776 and 2000, volume 2, pages 3527-3529).
- the conversion of the amide (XI) into the Mannich product (XU) is a one-pot reaction in which 2 to 4 phases are carried out, which are described below. All phases of the reaction are carried out in a fairly polar solvent with ether properties, which must have good solubility properties for lithium salts and good stability to lithium bases.
- Preferred solvents are tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, diethoxymethane (DEM, formaldehyde diethylacetal), 1,1-dimethoxymethane (methylal), diglyme (diethylene glycol dimethyl ether), triglyme (triethylene glycol dimethyl ether) and dichloromethane.
- Tetrahydrofuran and diethoxymethane, in particular tetrahydrofuran are particularly preferred.
- 1.1 to 5.0 equivalents of imine (DI) based on the amide enolate are used, preferably 1.3 to 4.0 equiv., Particularly preferably 1.5 to 2.0 equiv.
- the Mannich addition is used in 20 ° C to + 30 ° C, preferably at -10 ° C to + 20 ° C, particularly preferably at 0 ° C to + 10 ° C.
- 1.5 to 2.0 equiv. a 1 molar solution of imine (DI) in THF at 0 to + 10 ° C within 10 minutes to 1 equiv. a 0.2 to 0.5 molar solution of lithium enolate in THF, the 6 to 6.5 equiv. Lithium chloride contains and then stirred for 1 to 3 hours at this temperature.
- the reaction mixture is worked up and the Mannich product (XD) is isolated by the customary methods which are well known to those skilled in the art.
- amide cleavage of the ⁇ -alkyl-substituted ß-aryl-ß-arylammo-propionic acid pseudoephedrinamides (XD) of the present invention basic hydrolysis is preferred because under acidic conditions, impurities due to elimination reactions can arise and because the amide splitting in boiling water is very slow.
- Basic amide cleavage in boiling aqueous-ethanolic, sodium hydroxide solution can lead to a more or less large extent to the epimerization of the ⁇ -position, which must be suppressed as much as possible.
- the protective groups can optionally be reintroduced into the product of the amide cleavage reaction (formula XID) using methods known to the person skilled in the art [see “Protective Groups in Organic Synthesis” (TW Green, PGM Wuts (editor), John Wiley & Sons, Inc. , 1999)].
- R 9 then (C 1 -C 4 ) alkyl, CO (C 1 -C 4 ) alkyl, COO (CC) alkyl, SO 2 -Aryl - be converted into the ß-lactam (XIV). This can also be done directly from (XD).
- An overview of the possible reaction conditions can be found in "Methods of Organic Chemistry (Houben-Weyl)" (Volume 16b, pages 60 to 114, Georg Thieme Verlag Stuttgart, New York, 1991).
- This cyclization with 1 to 2 equivalents of the base LitWum-bis (trimethylsilyl) amide ( LHMDS) in the solvent THF
- LHMDS base LitWum-bis (trimethylsilyl) amide
- the cyclization is carried out in the temperature range from -40 ° C. to + 50 ° C., preferably at -20 ° C. to + 25 ° C., particularly preferably at -10 ° C. to 0 ° C.
- the protective groups can finally be split off by methods known to the person skilled in the art.
- Alkyl (-CC 4 ) alkyl, preferably (-C- 8 ) alkyl, unbranched or branched;
- Aryl (C 6 -C 10 ) aryl; p in front of a substituent like "pOCH 3 " means position 4 am
- Examples 1 to 14 and 18 to 35 show the preparation of preliminary or intermediate products, Examples 15 to 17 the production of diphenyl azetidinones or their deprotection. A reference example VI is also given for comparison purposes.
- the total yield (pale yellow resin) is thus 23.4 g (49.4 mmol, 92% HPLC [column: 250 x 4.6 mm (R, R) -Whelk 01; eluent: n-hexane / iPrOH 90:10; flow: 1 ml / min; temp .: 25 ° C ; Det .: 210 n, t ret 5 (S) -silanyloxy diastereomer 8.4 min .; peak of the same UV spectrum (probably 5 (R) -D iastereomer): t re t 7.4 min.] gives a diastereomeric purity of 96% de (de is the abbreviation for the diastereomeric excess "diastereomeric excess").
- the mixture is allowed to warm to 0 ° C., the reaction mixture becoming very cloudy at -30 ° C., and stirring is continued for a further 5 minutes at 0 ° C. It is cooled again to -78 ° C, forming a thick, difficult to stir porridge.
- a solution of 18.9 g (40.0 mmol) of the pseudoephedrinamide (from Example 3) in 80 ml of THF is added dropwise in a dropping funnel within 30 minutes.
- the cold bath is initially removed briefly, the Indoor temperature rises to a maximum of -50 ° C.
- the mixture quickly becomes thinner so that the reaction flask can be immersed in the cooling bath again.
- the mixture is stirred at -78 ° C for 1 hour.
- the contents can be determined from the HPLC peak areas of the imine-protected Mannich product or imine-deprotected Mannich product generated by these samples be read.
- the crude product accordingly contains 57% by weight of imine-protected Mannich product and 8% by weight of nin-deprotected Mannich product. This corresponds to a yield of 23.8 g (28.6 mmol, 71.4% of theory) of protected Mannich product and 3.3 g (4.6 mmol, 11.6% of theory) imine deprotected Mannich product.
- the overall yield of Mannich product is 33.2 mmol (83% of theory).
- the anisaldehyde is completely removed by extraction with 4 x 30 ml of n-heptane.
- 30 ml of dichloromethane are added to the acidic water phase and adjusted to pH 11 with vigorous stirring with 19.5 ml of 1N aqueous sodium hydroxide solution.
- the organic phase is separated off and the aqueous phase is extracted with 2 ⁇ 30 ml of dichloromethane.
- the combined dichloromethane extracts are dried over sodium sulfate, filtered, concentrated in vacuo and the residue is dried under high pressure. 1.09 g (1.53 mmol, 87% of theory) of pure product are obtained as a beige, amorphous solid.
- Complete removal of the anisaldehyde before basing the aqueous phase is essential. If anisaldehyde residues remain, the corresponding amount of the starting material is formed again.
- the reaction mixture is cooled, 20 ml of water are added and the mixture is then concentrated in vacuo to a total volume of about 20 ml in order to remove the ethanol.
- Another 20 ml of water are added to the aqueous residue and the mixture is concentrated again.
- the cloudy aqueous residue is washed with 2 x 20 ml of diethyl ether and then contains the products in a purity of 96 area% and in a ratio of 5: 1 according to HPLC analysis.
- the aqueous phase is in an ice bath with 14 ml of 2N Hydrochloric acid adjusted to pH 7, whereby a fluffy, yellow precipitate precipitates soon after the addition has started.
- the product is also chromatographed with an authentic sample from reference example 1. At -15 ° C., a further 135 ⁇ l (0.143 mmol) of 1.06 M solution of lithium bis (trimemylsilyl) amide in THF are added. HPLC control now shows complete conversion of the starting material into the product.
- the reaction mixture is mixed with 3 ml of saturated aqueous sodium hydrogen carbonate solution and extracted with 3 x 3 ml of dichloromethane. The organic phase is filtered, concentrated in vacuo and the residue is dried under HV. Yield: 90 mg (0.135 mmol, 94% of theory) of a yellow solid.
- Analytical HPLC (system as in Example 5): The starting material (t ret 19.9 min.) Completely passes into the product (t ret 17.1 min.).
- HPLC analysis shows, in addition to pyridine (t ret 4.8 min.) And 1.5 area% starting material (t r et 9.8 min.), The product in the form of two diastereomers (ratio approx. 1: 1, t r et 14.1 and 14.4 min.).
- the reaction solution is concentrated in vacuo to 70 ml, diluted with 100 ml of diethyl ether and washed with 1 x 100 ml and 2 x 50 ml of water.
- the organic phase was concentrated in vacuo and the residue dried in the HV. 9.70 g of a slightly yellowish oil are obtained which, according to HPLC, has a purity of 76 area%.
- HPLC analysis shows collidine (step 8.1 min.) And trityl chloride (t ret 14.3 min.), Product (t ⁇ 17.8 min.) And traces of starting material (t « * 9.8 min.).
- the mixture is cooled, diluted with 300 ml of dichloromethane, washed with 1 x 200 and 2 x 100 ml of 10% aqueous acetic acid, then with 2 x 100 ml saturated aqueous NaHCO 3 solution followed by 2 x 100 ml water.
- 100 ml of n-heptane are added to the organic phase (turbidity) and then concentrated in vacuo. An oil precipitates, which crystallizes after a short time.
- the mixture is cooled with ice and 30 ml of water are first added very slowly, then more rapidly. Two phases are formed. The majority of THF is distilled off in vacuo. The oil is extracted from the water phase with 3 x 15 ml of ethyl acetate, the pH being adjusted to 6 with 4 ml of 10% aqueous acetic acid in order to achieve a sufficient phase separation rate. The combined extracts are washed with 15 ml of saturated aqueous NaHCO 3 solution and with 15 ml of water, then the solvent is distilled off in vacuo. The residue is dried in an HV. 13.2 g of crude product are obtained as a yellow, voluminous solid foam which, according to HPLC, has a purity of 72 area%.
- a 3-necked flask with magnetic stirrer, septum and thermometer are used under argon to dissolve 1.91 g (44.7 mmol) of anhydrous lithium chloride and 3.74 g (22.2 mmol) of 98% (+) - pseudoephedrine in 30 ml of absolute THF at 0-2 ° C. in the course of 10 minutes using a syringe pump 3.56 ml (8.91 mmol) of a 2.5 molar solution of n-butyllithium in hexane were added dropwise.
- the mixture is cooled with ice and 30 ml of water are first added very slowly, then more rapidly. Two phases are formed.
- the majority of THF is distilled off in vacuo and the oil which separates is extracted with 1 x 30 ml and 2 x 15 ml of ethyl acetate, the pH being set to 6 with 4 ml of 10% aqueous acetic acid in order to achieve a sufficiently rapid phase separation.
- the combined organic extracts are washed with 15 ml of saturated aqueous NaHCO 3 solution and with 15 ml of water, concentrated in vacuo and the residue is dried under HV. 8.40 g of a yellowish oil is obtained, which slowly crystallizes.
- a glass column (diameter 7.0 cm, length 46 cm) is filled with 1770 ml (approx. 900 g) silica gel 60 (Merck, 0.04 - 0.063 mm) in a book medium pressure system.
- the column is conditioned at a flow of 130 ml / min with 1.5 L CH 2 C1 2 / MeOH / NfttOH (25%) 9: 1.5: 0.3, then with 2 L CH 2 C1 2 .
- the crude product, dissolved in 15 ml of CH 2 C1 2 is then applied to the column.
- Non-polar impurities are treated with 1 L CH 2 C1 2 followed by 0.5 L CH 2 C1 2 / MeOH 99: 1 followed by 0.5 L CH 2 C1 2 / MeOH 98: 2 followed by 0.5 L CH 2 C1 2 / MeOH 95: 5.
- the product, which is deprotected on the column, is then treated with 1 L CH 2 C1 2 / MeOH / NH 4 OH (25%) 9: 0.5: 0.1, followed by 3 L CH 2 C1 2 / MeOH / NH4OH (25%) 9: 1: 0.2, followed by 2 L CH 2 C1 2 / MeOH / NH 4 OH (25%) eluted 9: 1.5: 0.3. Approx.
- Lithium chloride (99%) is 3 hours at 150-200 ° C / 4 x 10 ° ⁇ 3. mbar dried.
- Diisopropylarnine (99.5%) is freshly distilled off from CaH 2 and then contains 0.02% by weight of water according to the Karl Fischer titration.
- THF is degassed using bubbling, dried argon and contains ⁇ 0.005% by weight of water according to the Karl Fischer titration.
- the column is conditioned at a flow of 130 ml / min with 1.5 L CH 2 C1 2 / MeOH / NE OH (25%) 9: 1.5: 0.3, then with 2 L CH 2 C1 2 ,
- the crude product, dissolved in 15 ml of CH 2 C1 2 is then applied to the column.
- Non-polar impurities are treated with 1 L CH 2 C1 2 followed by 0.5 L CH 2 C1 2 / MeOH 99: 1 followed by 0.5 L CH 2 C1 2 / MeOH 98: 2 followed by 0.5 L CH 2 C1 2 / MeOH 95: 5 eluted.
- the toluene prevents the product from being left behind from the ammonia when it is concentrated in water residues, in which it would suffer a retro Mannich reaction.
- the solvents are removed in vacuo and the residue is dried in an HV. 5.30 g of brown, amorphous, solid foam are obtained, which according to HPLC is 97% by area. Yield: 6.11 mmol corresponding to 63% of theory.
- Lithium chloride (99%) is dried for 3 hours at 150-200 ° C / 4 x 10 "3 mbar.
- Diisopropylamine (99.5%) is freshly distilled off from CaH 2 and then contains 0.02% by weight of water According to Karl Fischer titration Tetrahydrofuran (THF, Fluka) is degassed using bubbling, dried argon and contains ⁇ 0.005% by weight of water according to Karl Fischer titration.
- the column is conditioned at a flow of 130 ml / min with 3 L CH 2 C1 2 / MeOH / NH 4 OH (25%) 9: 1.5: 0.3, followed by 2 L CH 2 C1 2 . Then the crude product, dissolved in 30 ml CH 2 C1 2 , is applied to the column. Nonpolar associations are made with 1 L CH 2 C1 2 followed by .0.5 L CH 2 C1 2 / MeOH 99: 1 followed by 0.5 L CH 2 C1 2 / MeOH 98: 2 followed by 0.5 L. CH 2 C1 2 / MeOH 95: 5 eluted.
- Fractions 13-24 containing the pure Mannich main product, are combined with the introduction of toluene.
- the toluene prevents the product from being left behind from the ammonia when it is concentrated in water residues, in which it would suffer a retro Mannich reaction.
- the solvents were removed in vacuo and the residue was dried in an HV. 5.56 g of light brown, amorphous, solid foam are obtained, which according to HPLC is 99% by area. Yield: 8.37 mmol corresponding to 65% of theory.
- the aqueous solution is washed with 2 x 20 ml of diethyl ether.
- the aqueous solution is cooled in an ice bath and, by slowly adding dropwise 14.4 ml of 2N aqueous hydrochloric acid under control with a pH electrode starting from pH 13.2 to pH 7.5, an increasingly thick slurry of solid precipitates. It is suctioned off, washed with water and dried in an HV over phosphorus pentoxide.
- This crude product (2.57 g, 160% of theory) contains silicates which result from the action of the hot sodium hydroxide solution on the flask wall.
- the crude product is mixed with 125 ml of ethanol and the suspension is stirred for 2 hours at room temperature.
- the aqueous phase is cooled in an ice bath and slow 12.5 ml of 2N aqueous hydrochloric acid are added dropwise under control with a pH electrode starting from pH 13.2 to pH 7.5, an increasingly thick slurry of solid precipitating. It is suctioned off, washed with water and 1 dried in an HV over phosphorus pentoxide.
- This crude product (2.38 g, 136% of theory) contains silicates which result from the action of the hot sodium hydroxide solution on the flask wall.
- the crude product is mixed with 125 ml of ethanol and the suspension is stirred for 2 hours at room temperature. The undissolved residue is filtered off with a glass frit and washed several times with ethanol.
- the filtrate is cooled in an ice bath and, by slowly adding dropwise 13.4 ml of 2N aqueous hydrochloric acid under control with a pH electrode starting from pH 13.3 to pH 7.5, an increasingly thick yellow solid slurry precipitates. It is suctioned off, washed with water and dried in an HV over phosphorus pentoxide.
- This crude product (2.25 g, 146% of theory) contains silicates which were formed by the action of the hot sodium hydroxide solution on the flask wall.
- the crude product is mixed with 125 ml of ethanol and the suspension is stirred for 2 hours at room temperature.
- the undissolved colorless residue is filtered off with a glass frit and washed several times with ethanol.
- reaction mixture is poured onto 200 ml of ice-cooled 1% acetic acid (beaker) and stirred vigorously for 30 minutes. 50 ml of toluene are added, the ice bath is removed and the mixture is stirred vigorously at about 20 ° C. for a further hour.
- the clear, colorless, aqueous phase (bottom) is separated off and the light yellow, cloudy organic phase (top) is stirred vigorously for a further 1 hour with 50 ml of 1% aqueous acetic acid.
- the aqueous phase is separated off and the organic phase is dried over sodium sulfate.
- the commercial sodium tert-butoxide is sublimed in a high vacuum and stored under argon until it is used shortly afterwards in a desiccator.
- the toluene used is degassed over a predried molecular sieve (0.4 nm) for 5 minutes in an ultrasonic bath. Glass flasks are heated with hot air under a stream of argon. The solids are weighed in under a slight argon countercurrent. Solvent addition and sampling are carried out via a septum in the flask by means of syringes / cannulas, which are kept over phosphorus pentoxide until use in the desiccator.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05743217A EP1753717A1 (de) | 2004-05-21 | 2005-05-20 | Verfahren zur herstellung von diphenyl-azetidinon-derivaten |
CA002567481A CA2567481A1 (en) | 2004-05-21 | 2005-05-20 | Method for producing diphenyl azetidinone derivatives |
JP2007517093A JP2007538041A (ja) | 2004-05-21 | 2005-05-20 | ジフェニルアゼチジノン誘導体の製造方法 |
MXPA06013258A MXPA06013258A (es) | 2004-05-21 | 2005-05-20 | Metodo para producir derivados de difenil-azetidinona. |
AU2005245123A AU2005245123A1 (en) | 2004-05-21 | 2005-05-20 | Method for producing diphenyl azetidinone derivatives |
IL178993A IL178993A0 (en) | 2004-05-21 | 2006-11-01 | Method for producing diphenyl azetidinone derivatives |
US11/557,310 US7563888B2 (en) | 2004-05-21 | 2006-11-07 | Process for the preparation of diphenyl azetidinone derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004025072.3 | 2004-05-21 | ||
DE102004025072A DE102004025072A1 (de) | 2004-05-21 | 2004-05-21 | Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/557,310 Continuation US7563888B2 (en) | 2004-05-21 | 2006-11-07 | Process for the preparation of diphenyl azetidinone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005113495A1 true WO2005113495A1 (de) | 2005-12-01 |
Family
ID=34968088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/005497 WO2005113495A1 (de) | 2004-05-21 | 2005-05-20 | Verfahren zur herstellung von diphenyl-azetidinon-derivaten |
Country Status (13)
Country | Link |
---|---|
US (1) | US7563888B2 (de) |
EP (1) | EP1753717A1 (de) |
JP (1) | JP2007538041A (de) |
CN (1) | CN100582092C (de) |
AR (1) | AR049283A1 (de) |
AU (1) | AU2005245123A1 (de) |
CA (1) | CA2567481A1 (de) |
DE (1) | DE102004025072A1 (de) |
IL (1) | IL178993A0 (de) |
MX (1) | MXPA06013258A (de) |
TW (1) | TW200611895A (de) |
UY (1) | UY28913A1 (de) |
WO (1) | WO2005113495A1 (de) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008031131A (ja) * | 2006-08-01 | 2008-02-14 | Kotobuki Seiyaku Kk | オキサゾリジン誘導体の製造方法 |
WO2008108486A1 (ja) | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | 1-ビアリールアゼチジノン誘導体 |
WO2008106900A1 (en) * | 2007-03-02 | 2008-09-12 | Zentiva, A.S. | Method of manufacturing (3r, 4s) -1- (4-fluorophenyl) -3- [ (3s) -3- (4 -fluorophenyl) -3-hydroxypropyl) ] -4- (4-hyd roxyphenyl) -2-azetidinone |
US7470678B2 (en) | 2002-07-05 | 2008-12-30 | Astrazeneca Ab | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
US7842684B2 (en) | 2006-04-27 | 2010-11-30 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity |
US7863265B2 (en) | 2005-06-20 | 2011-01-04 | Astrazeneca Ab | 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia |
US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
US7893048B2 (en) | 2005-06-22 | 2011-02-22 | Astrazeneca Ab | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
US7906502B2 (en) | 2005-06-22 | 2011-03-15 | Astrazeneca Ab | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
WO2015039675A1 (en) | 2013-09-23 | 2015-03-26 | Pharmathen S.A. | Novel process for the preparation of ezetimibe intermediates |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ20031732A3 (cs) * | 2000-12-21 | 2003-09-17 | Aventis Pharma Deutschland Gmbh | 1,2-Difenylazetidinony a farmaceutické prostředky s jejich obsahem k léčení poruch metabolismu lipidů |
US20090047716A1 (en) * | 2007-06-07 | 2009-02-19 | Nurit Perlman | Reduction processes for the preparation of ezetimibe |
DE102007063671A1 (de) * | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
EP2414529A2 (de) | 2009-04-01 | 2012-02-08 | Matrix Laboratories Ltd | Enzymatisches verfahren zur herstellung von (s)-5-(4-fluorphenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-on, einer zwischenstufe von ezetimib, und weitere umwandlung zu ezetimib |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0524595A1 (de) * | 1991-07-23 | 1993-01-27 | Schering Corporation | Substituierte Beta-Lactam-Verbindungen als Hypocholesterolemische Mittel und Verfahren zu deren Herstellung |
-
2004
- 2004-05-21 DE DE102004025072A patent/DE102004025072A1/de not_active Withdrawn
-
2005
- 2005-05-20 AR ARP050102100A patent/AR049283A1/es not_active Application Discontinuation
- 2005-05-20 EP EP05743217A patent/EP1753717A1/de not_active Withdrawn
- 2005-05-20 CA CA002567481A patent/CA2567481A1/en not_active Abandoned
- 2005-05-20 AU AU2005245123A patent/AU2005245123A1/en not_active Abandoned
- 2005-05-20 UY UY28913A patent/UY28913A1/es unknown
- 2005-05-20 WO PCT/EP2005/005497 patent/WO2005113495A1/de not_active Application Discontinuation
- 2005-05-20 JP JP2007517093A patent/JP2007538041A/ja not_active Abandoned
- 2005-05-20 MX MXPA06013258A patent/MXPA06013258A/es active IP Right Grant
- 2005-05-20 CN CN200580016190A patent/CN100582092C/zh not_active Expired - Fee Related
- 2005-05-20 TW TW094116388A patent/TW200611895A/zh unknown
-
2006
- 2006-11-01 IL IL178993A patent/IL178993A0/en unknown
- 2006-11-07 US US11/557,310 patent/US7563888B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0524595A1 (de) * | 1991-07-23 | 1993-01-27 | Schering Corporation | Substituierte Beta-Lactam-Verbindungen als Hypocholesterolemische Mittel und Verfahren zu deren Herstellung |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7470678B2 (en) | 2002-07-05 | 2008-12-30 | Astrazeneca Ab | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
US7863265B2 (en) | 2005-06-20 | 2011-01-04 | Astrazeneca Ab | 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia |
US7893048B2 (en) | 2005-06-22 | 2011-02-22 | Astrazeneca Ab | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
US7906502B2 (en) | 2005-06-22 | 2011-03-15 | Astrazeneca Ab | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
US7842684B2 (en) | 2006-04-27 | 2010-11-30 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity |
JP2008031131A (ja) * | 2006-08-01 | 2008-02-14 | Kotobuki Seiyaku Kk | オキサゾリジン誘導体の製造方法 |
WO2008106900A1 (en) * | 2007-03-02 | 2008-09-12 | Zentiva, A.S. | Method of manufacturing (3r, 4s) -1- (4-fluorophenyl) -3- [ (3s) -3- (4 -fluorophenyl) -3-hydroxypropyl) ] -4- (4-hyd roxyphenyl) -2-azetidinone |
CZ302395B6 (cs) * | 2007-03-02 | 2011-04-27 | Zentiva, A. S. | Zpusob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu |
WO2008108486A1 (ja) | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | 1-ビアリールアゼチジノン誘導体 |
WO2015039675A1 (en) | 2013-09-23 | 2015-03-26 | Pharmathen S.A. | Novel process for the preparation of ezetimibe intermediates |
Also Published As
Publication number | Publication date |
---|---|
TW200611895A (en) | 2006-04-16 |
US20070149501A1 (en) | 2007-06-28 |
UY28913A1 (es) | 2005-12-30 |
EP1753717A1 (de) | 2007-02-21 |
AR049283A1 (es) | 2006-07-12 |
US7563888B2 (en) | 2009-07-21 |
JP2007538041A (ja) | 2007-12-27 |
CA2567481A1 (en) | 2005-12-01 |
DE102004025072A1 (de) | 2005-12-15 |
IL178993A0 (en) | 2007-03-08 |
CN100582092C (zh) | 2010-01-20 |
AU2005245123A1 (en) | 2005-12-01 |
CN1956951A (zh) | 2007-05-02 |
MXPA06013258A (es) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7563888B2 (en) | Process for the preparation of diphenyl azetidinone derivatives | |
DE69618812T2 (de) | Zwischerprodukte für die hemisynthese von taxanen und deren verfahren zu herstellung | |
DE69103265T2 (de) | Verfahren zur stereoselektiven herstellung von phenylisoserinderivaten. | |
DE69709742T2 (de) | Asymmetrische synthese von chiralen beta-aminosäuren | |
DE68916754T2 (de) | Verfahren zur Herstellung von optisch aktiver 3-Hydroxybuttersäure. | |
EP1682527B1 (de) | Verfahren zur herstellung von statinen | |
WO2021233783A1 (de) | Verfahren zur herstellung von butyl-(5s)-5-({2-[4-(butoxycarbonyl)phenyl]ethyl}[2-(2-{[3-chlor-4'-(trifluormethyl)[biphenyl]-4-yl]methoxy}phenyl)ethyl]amino)-5,6,7,8-tetrahydrochinolin-2-carboxylat | |
EP1648894A1 (de) | Verfahren zur herstellung von oh-geschützten [4-(2,6-diamino-9h- purin-9-yl)-1,3-dioxolan-2-yl]methanol-derivaten | |
DE60102825T2 (de) | Kinetische racematspaltung chiraler 2- und 3- substituierter carbonsäuren | |
EP1888600A2 (de) | Verfahren zur herstellung von statinen | |
DE69605144T2 (de) | Ein Verfahren zur Herstellung von einem optisch aktiven Azetidin-2-on-Derivat | |
DE69322013T2 (de) | (3R,5S)-3,5,6-Trihydroxyhexansäure Derivate und Verfahrens zur deren Herstellung | |
Soengas et al. | Synthesis of polyhydroxylated α-nitrocyclohexane carboxylic acids derived from d-glucose: a striking case of racemization | |
DE69910983T2 (de) | Synthese von chiralen beta-aminosäuren | |
DE69700477T2 (de) | Verfahren zur Herstellung von optisch aktivem 4-Hydroxy-2-Pyrrolidon | |
EP0279781A2 (de) | Verfahren zur Herstellung von 4-Acetoxy-3-hydroxyethyl-azetidinon | |
EP1412322A2 (de) | Geschützte 3,5-dihydroxy-2,2-dimethyl-valeroamide für die synthese von epothilonen und derivaten und verfarhen zur herstellung und die verwendung | |
DE60120991T2 (de) | Verfahren zu herstellung von discodermoliden und ähnlichen verbindungen | |
EP0651736A1 (de) | VERFAHREN ZUR HERSTELLUNG ENANTIOMERENREINER -SUBSTITUIERTER gamma-AMINOBUTTERSÄUREDERIVATE, NEUE ENANTIOMERENREINE ZWISCHENSTUFEN DIESES VERFAHRENS UND DEREN VERWENDUNG | |
DE19813821A1 (de) | Verfahren zur Herstellung von C1-C6-Bausteinen zur Totalsynthese von Epothilon und Epothilon-Derivaten | |
DE60301267T2 (de) | Verfahren zur herstellung von 4-oxytetrahydropyran-2-onen | |
EP0818447B1 (de) | 6-(Hydroxymethyl-ethyl)pyridine als HMG-CoA-Reduktase Inhibitoren | |
DE69331249T2 (de) | Verfahren zur Herstellung von (1'R,3S,4R)4-Acylthioazetidinonen | |
DE102011088854B4 (de) | Verfahren zur Herstellung von Sphingosin-1-phosphat | |
AT393838B (de) | Stereogesteuertes verfahren zur herstellung von neuen penem-verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 178993 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005743217 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11557310 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/013258 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007517093 Country of ref document: JP Ref document number: 2005245123 Country of ref document: AU Ref document number: 2567481 Country of ref document: CA Ref document number: 200580016190.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067024421 Country of ref document: KR Ref document number: 4290/CHENP/2006 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005245123 Country of ref document: AU Date of ref document: 20050520 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005245123 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067024421 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005743217 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11557310 Country of ref document: US |